Terms: = Gastric cancer AND CDX2, CDX3, 1045, ENSG00000165556, Q99626 AND Staging
3 results:
1. A novel nomogram and risk stratification system predicting the cancer-specific survival of patients with gastric neuroendocrine carcinoma: a study based on SEER database and external validation.
Song X; Xie Y; Lou Y
BMC Gastroenterol; 2023 Jul; 23(1):238. PubMed ID: 37452300
[TBL] [Abstract] [Full Text] [Related]
2. High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers.
Hur JY; Chao J; Kim K; Kim ST; Kim KM; Klempner SJ; Lee J
Pathol Res Pract; 2020 Apr; 216(4):152878. PubMed ID: 32089408
[TBL] [Abstract] [Full Text] [Related]
3. cdx2 as a prognostic marker in gastric cancer.
Masood MA; Loya A; Yusuf MA
Acta Gastroenterol Belg; 2016; 79(2):197-200. PubMed ID: 27382937
[TBL] [Abstract] [Full Text] [Related]
